{"id": "article-29998_0", "title": "Tetanus Toxoid -- Continuing Education Activity", "content": "The tetanus toxoid is a vaccine used in the management and treatment of tetanus. It is in the vaccine class of medications. This activity reviews the indications, action, and contraindications for the tetanus toxoid as a valuable agent in the immunization against tetanus and wound prophylaxis. This activity will highlight the mechanism of action, adverse event profile, and other key factors such as the administration and adverse effects pertinent for members of the health care team in treating patients with tetanus.", "contents": "Tetanus Toxoid -- Continuing Education Activity. The tetanus toxoid is a vaccine used in the management and treatment of tetanus. It is in the vaccine class of medications. This activity reviews the indications, action, and contraindications for the tetanus toxoid as a valuable agent in the immunization against tetanus and wound prophylaxis. This activity will highlight the mechanism of action, adverse event profile, and other key factors such as the administration and adverse effects pertinent for members of the health care team in treating patients with tetanus."}
{"id": "article-29998_1", "title": "Tetanus Toxoid -- Continuing Education Activity", "content": "Objectives: Describe the indications for the administration of the tetanus toxoid. Review the mechanism of action of the tetanus toxoid. Summarize the symptoms of tetanus. Explain the importance of knowing past immunizations to properly protect against tetanus. Access free multiple choice questions on this topic.", "contents": "Tetanus Toxoid -- Continuing Education Activity. Objectives: Describe the indications for the administration of the tetanus toxoid. Review the mechanism of action of the tetanus toxoid. Summarize the symptoms of tetanus. Explain the importance of knowing past immunizations to properly protect against tetanus. Access free multiple choice questions on this topic."}
{"id": "article-29998_2", "title": "Tetanus Toxoid -- Indications", "content": "The tetanus toxoid is an FDA-approved vaccination given alone or in conjunction with other vaccines. It is protective against effects from a gram-positive bacillus, Clostridium tetani. This bacteria produces a neurotoxin called\u00a0tetanospasmin, which\u00a0blocks the release of an inhibitory neurotransmitter and leads to unopposed\u00a0muscle contractions and spasms. [1]", "contents": "Tetanus Toxoid -- Indications. The tetanus toxoid is an FDA-approved vaccination given alone or in conjunction with other vaccines. It is protective against effects from a gram-positive bacillus, Clostridium tetani. This bacteria produces a neurotoxin called\u00a0tetanospasmin, which\u00a0blocks the release of an inhibitory neurotransmitter and leads to unopposed\u00a0muscle contractions and spasms. [1]"}
{"id": "article-29998_3", "title": "Tetanus Toxoid -- Indications", "content": "The World Health Organization recommends receiving the primary series of tetanus vaccinations during adolescence. Due to the requirement for primary immunization, an absorbed form containing multiple antigens is usually utilized. [2] Children must complete the 5-dose DTaP (diphtheria, tetanus, acellular pertussis) vaccination series before the age of 7. [3] The CDC recommends the first dose at two months old, the second dose at three months old, the third dose at four months old, the fourth dose between months 15 and 18, and the fifth dose between the ages of 4 and 6.\u00a0Following the first series of vaccinations, the recommendation is that adults receive boosters with Tdap (same components as DTaP, but reduced doses of diphtheria and pertussis) every ten years. Studies indicate that the Tdap booster given ten years after the initial series of vaccines is usually well-tolerated and effectively immunogenic. [4]", "contents": "Tetanus Toxoid -- Indications. The World Health Organization recommends receiving the primary series of tetanus vaccinations during adolescence. Due to the requirement for primary immunization, an absorbed form containing multiple antigens is usually utilized. [2] Children must complete the 5-dose DTaP (diphtheria, tetanus, acellular pertussis) vaccination series before the age of 7. [3] The CDC recommends the first dose at two months old, the second dose at three months old, the third dose at four months old, the fourth dose between months 15 and 18, and the fifth dose between the ages of 4 and 6.\u00a0Following the first series of vaccinations, the recommendation is that adults receive boosters with Tdap (same components as DTaP, but reduced doses of diphtheria and pertussis) every ten years. Studies indicate that the Tdap booster given ten years after the initial series of vaccines is usually well-tolerated and effectively immunogenic. [4]"}
{"id": "article-29998_4", "title": "Tetanus Toxoid -- Indications", "content": "Furthermore, tetanus toxoid can be used alone if needed in particular circumstances. It is highly effective when used prophylactically in cases when dealing with wound care and management. The Tdap booster vaccination should also be considered in patients with any wound injury who have had less than three tetanus toxoid doses, received their last dose more than ten years ago, or if their immunization history is unknown. [5]", "contents": "Tetanus Toxoid -- Indications. Furthermore, tetanus toxoid can be used alone if needed in particular circumstances. It is highly effective when used prophylactically in cases when dealing with wound care and management. The Tdap booster vaccination should also be considered in patients with any wound injury who have had less than three tetanus toxoid doses, received their last dose more than ten years ago, or if their immunization history is unknown. [5]"}
{"id": "article-29998_5", "title": "Tetanus Toxoid -- Mechanism of Action", "content": "Vaccinations exert their effect on the human body via priming our active immune system. Following the administration of the tetanus toxoid, the immune system\u00a0is stimulated and responds to the antigens present in the vaccine. TH2 and B cells are\u00a0activated, which then produce immunoglobins against the toxoid,\u00a0allowing for adequate protection against future infections. This process requires multiple dosages to achieve a high immune response; however, it bears mentioning that there is no chance for the toxoid to exhibit its pathogenic features as it is an inactivated vaccine. [6]", "contents": "Tetanus Toxoid -- Mechanism of Action. Vaccinations exert their effect on the human body via priming our active immune system. Following the administration of the tetanus toxoid, the immune system\u00a0is stimulated and responds to the antigens present in the vaccine. TH2 and B cells are\u00a0activated, which then produce immunoglobins against the toxoid,\u00a0allowing for adequate protection against future infections. This process requires multiple dosages to achieve a high immune response; however, it bears mentioning that there is no chance for the toxoid to exhibit its pathogenic features as it is an inactivated vaccine. [6]"}
{"id": "article-29998_6", "title": "Tetanus Toxoid -- Administration", "content": "Preparation of the tetanus toxoid is via\u00a0inactivation of the toxigenic strains of Clostridium tetani. The toxic strains are grown in liquid media, purified, then treated with formaldehyde to take away the pathogenic properties.\u00a0Following purification and sterilization, tetanus toxoid is combined with aluminum or calcium salts. This toxoid antigen is then usually used in combination with Diptheria and pertussis antigens in a vaccination form.", "contents": "Tetanus Toxoid -- Administration. Preparation of the tetanus toxoid is via\u00a0inactivation of the toxigenic strains of Clostridium tetani. The toxic strains are grown in liquid media, purified, then treated with formaldehyde to take away the pathogenic properties.\u00a0Following purification and sterilization, tetanus toxoid is combined with aluminum or calcium salts. This toxoid antigen is then usually used in combination with Diptheria and pertussis antigens in a vaccination form."}
{"id": "article-29998_7", "title": "Tetanus Toxoid -- Administration", "content": "The DTaP vaccine is a 0.5 mL dose, and it is given intramuscularly. For patients who are infants to two years old, the anterolateral aspect of the thigh is the preferred injection site.\u00a0 For children aged three and older, the deltoid muscle is the preferred injection site. [1] This regimen is a 5-dose series starting at the age of two months and ending at six years old. First dose: 2 months old, must be at least six weeks old Second dose: 4 months old Third dose: 6 months old Fourth dose: 15 months to 18 months old, must be at least 12 months old, given at a minimum of six months after the third dose Fith dose: 4 years to 6 years old, must be at least four years old, given at a minimum of six months after the fourth dose", "contents": "Tetanus Toxoid -- Administration. The DTaP vaccine is a 0.5 mL dose, and it is given intramuscularly. For patients who are infants to two years old, the anterolateral aspect of the thigh is the preferred injection site.\u00a0 For children aged three and older, the deltoid muscle is the preferred injection site. [1] This regimen is a 5-dose series starting at the age of two months and ending at six years old. First dose: 2 months old, must be at least six weeks old Second dose: 4 months old Third dose: 6 months old Fourth dose: 15 months to 18 months old, must be at least 12 months old, given at a minimum of six months after the third dose Fith dose: 4 years to 6 years old, must be at least four years old, given at a minimum of six months after the fourth dose"}
{"id": "article-29998_8", "title": "Tetanus Toxoid -- Administration", "content": "As most DTaP vaccinations contain higher levels of diphtheria\u00a0compared to tetanus and pertussis, Tdap has higher levels of tetanus\u00a0than diphtheria and pertussis.\u00a0The Tdap vaccine is a 0.5 mL dose, and it is also given as an intramuscular injection.\u00a0This vaccine should only be used as a booster every ten years, starting at ages eleven to twelve.", "contents": "Tetanus Toxoid -- Administration. As most DTaP vaccinations contain higher levels of diphtheria\u00a0compared to tetanus and pertussis, Tdap has higher levels of tetanus\u00a0than diphtheria and pertussis.\u00a0The Tdap vaccine is a 0.5 mL dose, and it is also given as an intramuscular injection.\u00a0This vaccine should only be used as a booster every ten years, starting at ages eleven to twelve."}
{"id": "article-29998_9", "title": "Tetanus Toxoid -- Adverse Effects", "content": "Although vaccinations containing the tetanus toxoid are generally safe, some adverse effects can occur.\u00a0 Any vaccine with tetanus toxoid as a component has the potential to cause brachial neuritis. [7] Also known as neuralgic amyotrophy,\u00a0 brachial neuritis is an immune-mediated inflammatory process involving peripheral nerves.\u00a0 Patients usually present with pain and muscle weakness, and sometimes cases can be severe; however, this is extremely rare, and symptoms typically subside on their own. [8] A\u00a0study of 740 patients with adverse effects to the tetanus toxoid showed that, when present, the most common symptoms are local edema and tenderness, fever, and anaphylactoid response. [9]", "contents": "Tetanus Toxoid -- Adverse Effects. Although vaccinations containing the tetanus toxoid are generally safe, some adverse effects can occur.\u00a0 Any vaccine with tetanus toxoid as a component has the potential to cause brachial neuritis. [7] Also known as neuralgic amyotrophy,\u00a0 brachial neuritis is an immune-mediated inflammatory process involving peripheral nerves.\u00a0 Patients usually present with pain and muscle weakness, and sometimes cases can be severe; however, this is extremely rare, and symptoms typically subside on their own. [8] A\u00a0study of 740 patients with adverse effects to the tetanus toxoid showed that, when present, the most common symptoms are local edema and tenderness, fever, and anaphylactoid response. [9]"}
{"id": "article-29998_10", "title": "Tetanus Toxoid -- Adverse Effects", "content": "In the 1990s, whole-cell pertussis was replaced with acellular pertussis, which is a common component of vaccines containing the tetanus toxoid. Before the switch to acellular pertussis,\u00a0swelling, redness, and pain at the injection site were commonly noted adverse events; however, these reactions are much less common today. [10]", "contents": "Tetanus Toxoid -- Adverse Effects. In the 1990s, whole-cell pertussis was replaced with acellular pertussis, which is a common component of vaccines containing the tetanus toxoid. Before the switch to acellular pertussis,\u00a0swelling, redness, and pain at the injection site were commonly noted adverse events; however, these reactions are much less common today. [10]"}
{"id": "article-29998_11", "title": "Tetanus Toxoid -- Contraindications", "content": "The tetanus toxoid is generally safe for the human population; however, there are specific contraindications. One contraindication includes past anaphylaxis reaction to the tetanus toxoid.\u00a0Further, in the case where encephalopathy occurs within seven days of administration of the tetanus toxoid and no other cause is found,\u00a0this can also be a contraindication for future injections. [1]", "contents": "Tetanus Toxoid -- Contraindications. The tetanus toxoid is generally safe for the human population; however, there are specific contraindications. One contraindication includes past anaphylaxis reaction to the tetanus toxoid.\u00a0Further, in the case where encephalopathy occurs within seven days of administration of the tetanus toxoid and no other cause is found,\u00a0this can also be a contraindication for future injections. [1]"}
{"id": "article-29998_12", "title": "Tetanus Toxoid -- Monitoring", "content": "Since the tetanus toxoid is generally safe and rarely leads to any severe issues, monitoring is not necessary.\u00a0However, if a patient wanted to know their immunity status against tetanus, this could be accomplished by using multi-analyte fluorescent detection. It\u00a0can detect the antibody titer level in their blood, confirming whether or not there is full immunity.\u00a0A level of higher than 0.01 IU/ml rates as a protective concentration of tetanus antibodies. [11]", "contents": "Tetanus Toxoid -- Monitoring. Since the tetanus toxoid is generally safe and rarely leads to any severe issues, monitoring is not necessary.\u00a0However, if a patient wanted to know their immunity status against tetanus, this could be accomplished by using multi-analyte fluorescent detection. It\u00a0can detect the antibody titer level in their blood, confirming whether or not there is full immunity.\u00a0A level of higher than 0.01 IU/ml rates as a protective concentration of tetanus antibodies. [11]"}
{"id": "article-29998_13", "title": "Tetanus Toxoid -- Monitoring", "content": "There is the possibility of an Arthus reaction (type III hypersensitivity) occurring after administering vaccines\u00a0containing\u00a0tetanus\u00a0toxoids. Possible symptoms include, but are not limited to, severe pain, swelling, induration, edema, hemorrhage, and occasionally necrosis. However, it bears mention that this is extremely rare and usually self-limited.\u00a0 Furthermore, a history of an Arthus reaction is not a contraindication to the tetanus toxoid. [3]", "contents": "Tetanus Toxoid -- Monitoring. There is the possibility of an Arthus reaction (type III hypersensitivity) occurring after administering vaccines\u00a0containing\u00a0tetanus\u00a0toxoids. Possible symptoms include, but are not limited to, severe pain, swelling, induration, edema, hemorrhage, and occasionally necrosis. However, it bears mention that this is extremely rare and usually self-limited.\u00a0 Furthermore, a history of an Arthus reaction is not a contraindication to the tetanus toxoid. [3]"}
{"id": "article-29998_14", "title": "Tetanus Toxoid -- Toxicity", "content": "There is no antidote or treatment for the tetanus toxoid.\u00a0 In the rare case of an anaphylactic reaction, it\u00a0is treatable with epinephrine. [12]", "contents": "Tetanus Toxoid -- Toxicity. There is no antidote or treatment for the tetanus toxoid.\u00a0 In the rare case of an anaphylactic reaction, it\u00a0is treatable with epinephrine. [12]"}
{"id": "article-29998_15", "title": "Tetanus Toxoid -- Enhancing Healthcare Team Outcomes", "content": "Advancements in vaccinations are responsible for the decrease in multiple different infectious diseases.\u00a0When inquiring about patients' past immunizations, we always have to consider the possibility of receiving false information.\u00a0A study done in 2012 involved asking patients about their tetanus vaccination, then drawing titer levels to see if they were correct.\u00a0This study enrolled 163 patients, and it showed that 12.8% of patients who stated their tetanus shot is up to date were not seropositive.\u00a0Twenty-six people were seronegative, and all of these patients had been to a doctor in the past year. This data shows the untrustworthy nature of the immunization history given by patients. [11]", "contents": "Tetanus Toxoid -- Enhancing Healthcare Team Outcomes. Advancements in vaccinations are responsible for the decrease in multiple different infectious diseases.\u00a0When inquiring about patients' past immunizations, we always have to consider the possibility of receiving false information.\u00a0A study done in 2012 involved asking patients about their tetanus vaccination, then drawing titer levels to see if they were correct.\u00a0This study enrolled 163 patients, and it showed that 12.8% of patients who stated their tetanus shot is up to date were not seropositive.\u00a0Twenty-six people were seronegative, and all of these patients had been to a doctor in the past year. This data shows the untrustworthy nature of the immunization history given by patients. [11]"}
{"id": "article-29998_16", "title": "Tetanus Toxoid -- Enhancing Healthcare Team Outcomes", "content": "The usage of reminders has been a topic of study in Canada in a trial containing 8069 patients who were 20 or older and split into three groups. In one group, the physician was reminded at the office visit to assess the patient's tetanus protection; the second group was reminded via phone call, while the third group received a reminder letter.\u00a0Statistics showed the most significant compliance occurred when the patients were given a letter as a reminder. With these reminder systems, researchers noted an increase in the rate of recorded tetanus vaccination, but it was well short of complete population coverage. These results show that\u00a0to achieve complete population coverage, more intense intervention is necessary. [13]", "contents": "Tetanus Toxoid -- Enhancing Healthcare Team Outcomes. The usage of reminders has been a topic of study in Canada in a trial containing 8069 patients who were 20 or older and split into three groups. In one group, the physician was reminded at the office visit to assess the patient's tetanus protection; the second group was reminded via phone call, while the third group received a reminder letter.\u00a0Statistics showed the most significant compliance occurred when the patients were given a letter as a reminder. With these reminder systems, researchers noted an increase in the rate of recorded tetanus vaccination, but it was well short of complete population coverage. These results show that\u00a0to achieve complete population coverage, more intense intervention is necessary. [13]"}
{"id": "article-29998_17", "title": "Tetanus Toxoid -- Enhancing Healthcare Team Outcomes", "content": "Tetanus toxoid vaccine requires an interprofessional approach to optimize its protective effects. This includes clinicians, infectious disease specialists, mid-level practitioners, nurses, and pharmacists. Meticulous record-keeping is a must and understanding the patient's current vaccine status, potential contraindications, and proper scheduling are all factors that will benefit from interprofessional communication and coordination. [Levle 5]", "contents": "Tetanus Toxoid -- Enhancing Healthcare Team Outcomes. Tetanus toxoid vaccine requires an interprofessional approach to optimize its protective effects. This includes clinicians, infectious disease specialists, mid-level practitioners, nurses, and pharmacists. Meticulous record-keeping is a must and understanding the patient's current vaccine status, potential contraindications, and proper scheduling are all factors that will benefit from interprofessional communication and coordination. [Levle 5]"}
{"id": "article-29998_18", "title": "Tetanus Toxoid -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Tetanus Toxoid -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}